Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 3.84
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of TVRD is 9.0 and suggests 139% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Data is available to registered users only
Buy
Sell